Pages that link to "Q34199560"

The following pages link to Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial (Q34199560):

Displaying 40 items.

• Current global status & impact of human papillomavirus vaccination: Implications for India (Q28079776) (← links)
• Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial (Q28607942) (← links)
• Oral sex and oropharyngeal cancer: The role of the primary care physicians. (Q30248928) (← links)
• Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica (Q30300329) (← links)
• Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections. (Q30353668) (← links)
• Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. (Q30354637) (← links)
• Health disparities and cancer: racial disparities in cancer mortality in the United States, 2000-2010. (Q35437586) (← links)
• Association Study between Cervical Lesions and Single or Multiple Vaccine-Target and Non-Vaccine Target Human Papillomavirus (HPV) Types in Women from Northeastern Brazil (Q35691927) (← links)
• Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda (Q36092294) (← links)
• Vaccination Programs for Endemic Infections: Modelling Real versus Apparent Impacts of Vaccine and Infection Characteristics (Q36180041) (← links)
• An Ethical Justification for Expanding the Notion of Effectiveness in Vaccine Post-Market Monitoring: Insights from the HPV Vaccine in Canada (Q36652379) (← links)
• Less than 3 doses of the HPV vaccine - Review of efficacy against virological and disease end points (Q37135074) (← links)
• Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial. (Q37609451) (← links)
• Next generation vaccines and vectors: Designing downstream processes for recombinant protein-based virus-like particles (Q38423724) (← links)
• Present status of human papillomavirus vaccine development and implementation (Q38460201) (← links)
• Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging (Q38460217) (← links)
• Cervical cancer: A comprehensive approach towards extermination (Q38748682) (← links)
• Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment (Q38906082) (← links)
• Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. (Q39635628) (← links)
• HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis (Q40050669) (← links)
• HPV vaccination initiation after the routine-recommended ages of 11-12 in the United States (Q40090268) (← links)
• HPV genotypes co-infections associated with cervical carcinoma: Special focus on phylogenetically related and non-vaccine targeted genotypes. (Q46257079) (← links)
• Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline (Q47111040) (← links)
• Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions. (Q47547829) (← links)
• Safety of Human Papillomavirus Vaccines: An Updated Review (Q49564347) (← links)
• Design and statistical considerations for studies evaluating the efficacy of a single dose of the human papillomavirus (HPV) vaccine. (Q52688140) (← links)
• Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. (Q54217505) (← links)
• Proposal for cervical cancer screening in the era of HPV vaccination. (Q55398396) (← links)
• Human Papillomavirus Vaccination: Making Sense of the Public Controversy (Q57089326) (← links)
• Human papillomavirus vaccination for men: advancing policy and practice (Q58452367) (← links)
• The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease (Q90055122) (← links)
• Prevalence of HPV infection among sexually active adolescents and young adults in Brazil: The POP-Brazil Study (Q90438579) (← links)
• Cervicovaginal microbiome and natural history of HPV in a longitudinal study (Q90666367) (← links)
• A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years (Q91576754) (← links)
• Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules (Q91644007) (← links)
• The effectiveness of vaccination to prevent the papillomavirus infection: a systematic review and meta-analysis (Q91818565) (← links)
• Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial (Q91874433) (← links)
• The nonavalent vaccine: a review of high-risk HPVs and a plea to the CDC (Q92899721) (← links)
• Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines (Q97881232) (← links)
• Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial (Q104060415) (← links)